Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia

Figure 1 Study flow chart. This study enrolled 146 subjects with functional dyspepsia and, after excluding 30 subjects for non-attendance and two for non-compliance, 57 subjects in each treatment group completed the study.

Figure 2 Change in dysmotility-like dyspepsia symptom score over time. Significantly greater improvement was seen in dysmotility-like dyspepsia symptom score on day 28 of treatment in the proton pump inhibitor (PPI) group than in the H₂-receptor antagonist (H₂RA) + prokinetic (Prok) group. No significant additional symptomatic improvement was seen after day 7 of H₂RA + Prok treatment, whereas further symptomatic improvements were seen over time in the PPI group. ^aP < 0.05, PPI vs H₂RA + Prok; ^cP < 0.05 vs pre-Rx in each group; ^eP < 0.05 vs 7 d Rx in each group.

Figure 3 Change in dysmotility-like dyspepsia symptom score over time according to Helicobacter pylori status. Significantly greater symptomatic improvement was seen in the proton pump inhibitor group than in the H₂-receptor antagonist (H₂RA) + prokinetic (Prok) group after 28 d of treatment, regardless of Helicobacter pylori (H. pylori) status. No additional significant symptomatic improvement was seen after day 7 of H₂RA + Prok treatment, regardless of H. pylori status. ^aP < 0.05, PPI vs H₂RA + Prok; ^cP < 0.05 vs pre-Rx in each group; ^eP < 0.05 vs 7 d Rx in each group.

Figure 4 Subject satisfaction after 14 d and 28 d of treatment. Subject satisfaction was significantly higher in the proton pump inhibitor (PPI) group than in the H₂-receptor antagonist (H₂RA) + prokinetic (Prok) group on day 28 of treatment. No significant increase in subject satisfaction was seen in the H₂RA + Prok group between days 14 and 28, whereas a significant increase was seen in the PPI group between days 14 and 28. ^aP < 0.05, PPI vs H₂RA + Prok; ^cP < 0.05 vs 14 d Rx.